Interestingly, MET induces MAPK re-activation in all tested HNSCC models, and blocking of MAPK with a MET inhibitor re-sensitized the HGF-stimulated tumor cells to cetuximab [71]. The gene discussed is HGF; the disease is head and neck squamous cell carcinoma.